Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of bezafibrate in mitochondrial fatty acid β-oxidation disorders (HUPE-002-03)
jRCTs011180008Completed
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of bezafibrate in fatty acid oxidation disorders (FAOD). Primary endpoint: Safety endpoint. Started Aug 2015; status: completed.
02
Drugs
bezafibrate
03
Conditions
fatty acid oxidation disorders (FAOD)
Beyond the preview
Go deeper on jRCTs011180008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011180008.